General Information of Drug Combination (ID: DCBP3YY)

Drug Combination Name
Oxytocin Phenylephrine
Indication
Disease Entry Status REF
Postpartum Hemorrhage Phase 1 [1]
Component Drugs Oxytocin   DMDL27I Phenylephrine   DMZHUO5
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Oxytocin
Disease Entry ICD 11 Status REF
Autism spectrum disorder 6A02 Approved [2]
Ductal breast carcinoma in situ N.A. Approved [3]
Postpartum haemorrhage JA43 Approved [3]
Lactation failure JB46.3 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Oxytocin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Agonist [9]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Agonist [10]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Agonist [11]
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Modulator [12]
------------------------------------------------------------------------------------
Oxytocin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Increases Expression [13]
------------------------------------------------------------------------------------
Indication(s) of Phenylephrine
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [6]
Arrhythmia BC9Z Approved [6]
Common cold CA00 Approved [6]
Cough MD12 Approved [6]
Fecal incontinence ME07 Approved [7]
Fever MG26 Approved [6]
Headache 8A80-8A84 Approved [6]
Mydriasis LA11.62 Approved [6]
Ophthalmic graves disease 5A02.0 Approved [8]
Proctitis DB33.Z Approved [6]
Rhinitis FA20 Approved [6]
Seasonal allergic rhinitis CA08.01 Approved [6]
Vasomotor/allergic rhinitis CA08 Approved [6]
Phenylephrine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [14]
------------------------------------------------------------------------------------
Phenylephrine Interacts with 34 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [15]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [16]
Carbonic anhydrase 1 (CA1) OTNFBVVQ CAH1_HUMAN Decreases Activity [17]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Decreases Activity [17]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [18]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Increases Secretion [16]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [18]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [15]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Increases Expression [19]
Alpha-1D adrenergic receptor (ADRA1D) OTW2CD1O ADA1D_HUMAN Increases Activity [20]
Alpha-1A adrenergic receptor (ADRA1A) OTUIWCL5 ADA1A_HUMAN Increases Activity [20]
Alpha-1B adrenergic receptor (ADRA1B) OTSAYAFD ADA1B_HUMAN Increases Activity [20]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [21]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [15]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Affects Activity [15]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [15]
Myosin regulatory light chain 2, atrial isoform (MYL7) OT7ZNDP4 MLRA_HUMAN Increases Phosphorylation [22]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [15]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [15]
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) OTC41R1E RIPK1_HUMAN Increases Expression [15]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Affects Activity [15]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4) OTTDCUAO NFAC4_HUMAN Increases Localization [23]
Mixed lineage kinase domain-like protein (MLKL) OTDSLC81 MLKL_HUMAN Increases Expression [15]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [15]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Affects Expression [24]
Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) OTL1D484 RIPK3_HUMAN Increases Expression [15]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Decreases Response To Substance [25]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Increases Response To Substance [26]
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Affects Response To Substance [27]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4) OTMWFDAC AT2B4_HUMAN Increases Response To Substance [28]
Beta-3 adrenergic receptor (ADRB3) OTPMG4V7 ADRB3_HUMAN Increases Response To Substance [29]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Affects Response To Substance [30]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Increases Response To Substance [31]
Caveolin-3 (CAV3) OTWSFDB4 CAV3_HUMAN Decreases Response To Substance [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 34 DOT(s)

References

1 ClinicalTrials.gov (NCT06285396) Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
3 Oxytocin FDA Label
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
5 Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
6 Isoproterenol FDA Label
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019494)
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 485).
9 The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
11 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
13 Oxytocin inhibits ox-LDL-induced adhesion of monocytic THP-1 cells to human brain microvascular endothelial cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:104-110. doi: 10.1016/j.taap.2017.10.022. Epub 2017 Nov 2.
14 MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64.
15 Phenylephrine induces necroptosis and apoptosis in corneal epithelial cells dose- and time-dependently. Toxicology. 2019 Dec 1;428:152305. doi: 10.1016/j.tox.2019.152305. Epub 2019 Oct 9.
16 [Effects of phenylephrine on atrial natriuretic factor and the renin-aldosterone axis in normal patients and essential hypertensive patients]. Arch Mal Coeur Vaiss. 1988 Jun;81 Spec No:75-8.
17 Synephrine and phenylephrine act as -amylase, -glycosidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase enzymes inhibitors. J Biochem Mol Toxicol. 2017 Nov;31(11). doi: 10.1002/jbt.21973. Epub 2017 Aug 11.
18 The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. J Hypertens. 2002 Feb;20(2):287-94. doi: 10.1097/00004872-200202000-00019.
19 Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res. 2006 Jul;54(1):57-64. doi: 10.1016/j.phrs.2006.02.006. Epub 2006 Feb 28.
20 Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
21 Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor. J Biol Chem. 2000 Apr 21;275(16):11846-51. doi: 10.1074/jbc.275.16.11846.
22 Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res. 2005 Jan 1;65(1):211-20. doi: 10.1016/j.cardiores.2004.09.019.
23 Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2005 Dec;289(6):L1061-74. doi: 10.1152/ajplung.00096.2005. Epub 2005 Jul 29.
24 The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond). 2009 Oct 19;118(2):137-45. doi: 10.1042/CS20080637.
25 Adrenomedullin contributes to vascular hyporeactivity in cirrhotic rats with ascites via a release of nitric oxide. Scand J Gastroenterol. 2004 Jul;39(7):686-93. doi: 10.1080/00365520410005306.
26 Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. J Hypertens. 2006 Jul;24(7):1355-63. doi: 10.1097/01.hjh.0000234116.17778.63.
27 Influence of angiotensin-I-converting-enzyme insertion/deletion gene polymorphism on perioperative hemodynamics after coronary bypass graft surgery. J Cardiovasc Surg (Torino). 2008 Apr;49(2):255-60.
28 Plasma membrane calcium ATPase overexpression in arterial smooth muscle increases vasomotor responsiveness and blood pressure. Circ Res. 2003 Oct 3;93(7):614-21. doi: 10.1161/01.RES.0000092142.19896.D9. Epub 2003 Aug 21.
29 Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol. 2005 Jul 19;46(2):351-9. doi: 10.1016/j.jacc.2005.03.061.
30 Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice. Br J Pharmacol. 2002 Jan;135(1):143-54. doi: 10.1038/sj.bjp.0704440.
31 Effect of sodium depletion on pressor responsiveness in ACTH-induced hypertension in man. Clin Exp Pharmacol Physiol. 1987 Mar;14(3):237-42. doi: 10.1111/j.1440-1681.1987.tb00382.x.
32 Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension. 2003 Aug;42(2):213-9. doi: 10.1161/01.HYP.0000082926.08268.5D. Epub 2003 Jul 7.